Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesPharmacy & Specialty DrugsMass General Brigham Evenity Prior Auth | OpenPaye…
    Ask Trek AI about this page
    CurrentMass General Brigham Health PlanPolicy N/A

    Treatment of Osteoporosis

    Customize your policy alerts

    Sign up for all Mass General Brigham Health Plan policy alerts

    Know when Mass General Brigham Health Plan releases new policies or updates existing guidance.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    This policy governs prior authorization for medically administered Evenity (romosozumab-aqqg) under the MassHealth UPPL medical benefit. It applies to treatment of osteoporosis in postmenopausal women and, off-label, in biologic males or members assigned male sex at birth who meet specified clinical and prior-treatment criteria.

    Policy Summary
    PayerMass General Brigham Health Plan
    PolicyTreatment of Osteoporosis
    Policy CodePolicy N/A
    Change TypeMaterial coverage criteria revision
    Effective DateJan 4, 202748d
    Last ReviewNov 4, 2026
    Next Review DateN/A
    Key ActionSubmit the requested clinical information and supporting medical records for Evenity prior authorization.
    SourceLink
    POLICY UPDATE CHANGES

    The policy removed prevention of osteoporosis as an indication for Evenity.

    The policy separated treatment of osteoporosis in biologic males or members assigned male sex at birth as an off-label indication.

    12 monthsMaximum total Evenity treatment duration
    T-score ≤ -2.5Bone mineral density threshold for osteoporosis
    MassHealth UPPLApplicable plan/program
    Prior authorization

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    Utilization management program
    90 daysNew-plan-member lookback period for documenting current therapy

    Coverage Criteria

    Postmenopausal osteoporosis

    Authorization may be granted when all of the following criteria are met for treatment of postmenopausal osteoporosis.

    Postmenopausal osteoporosis criteria

    • Diagnosis and BMD: Indication for treatment of postmenopausal osteoporosis and BMD indicating osteoporosisT-score ≤ -2.5
    • Initial oral-bisphosphonate or very-high-risk pathway

      • Oral bisphosphonate pathway: Inadequate response to an adequate trial or adverse reaction to one oral bisphosphonateone oral bisphosphonate
      • Oral bisphosphonate contraindication: Contraindication to all oral bisphosphonatesall oral bisphosphonates
      • Very high fracture risk: At least one very-high-fracture-risk factorHistory of fracture within the past 12 months; fractures while on osteoporosis therapy; multiple fractures; fractures while on drugs causing skeletal harm such as long-term glucocorticoids; T-score less than -3.0; high risk for falls; history of injurious falls; or very high fracture probability by FRAX or another validated fracture-risk algorithm
    • Additional therapy or severe osteoporosis pathway

      • Therapy response or contraindication pathway: Inadequate response to an adequate trial or adverse reaction with one, or contraindication to all, of denosumab, ibandronate injection, and zoledronic acid 5 mgdenosumab; ibandronate injection; zoledronic acid 5 mg
      • Severe osteoporosis: At least one severe-osteoporosis featureHistory of fragility fracture within the last 12 months; fractures while on osteoporosis therapy; T-score less than -3.0; or T-score of -2.5 or below plus a fragility fracture
    • Teriparatide prerequisite: Inadequate response, adverse reaction, or contraindication to teriparatide 560 mcg/2.24 mL560 mcg/2.24 mL

      Bonsity or Forteo

    Osteoporosis in biologic male or male sex assigned at birth

    Authorization may be granted when all of the following criteria are met for treatment of osteoporosis in a biologic male or member assigned male sex at birth; this is an off-label indication.

    Biologic male or male sex assigned at birth criteria

    • Diagnosis and BMD: Diagnosis of osteoporosis requiring treatment in a biologic male or member assigned male sex at birth and BMD indicating osteoporosisT-score ≤ -2.5
    • Initial oral-bisphosphonate or very-high-risk pathway

      • Oral bisphosphonate pathway: Inadequate response to an adequate trial or adverse reaction to one oral bisphosphonateone oral bisphosphonate
      • Oral bisphosphonate contraindication:

    Continuation therapy

    Reauthorization is available only before completion of 12 months of treatment.

    Continuation therapy: The member has not completed 12 months of Evenity treatment and the total treatment duration will not exceed 12 monthsmaximum 12 months

    For members new to the plan, medical records must document that the member is currently receiving Evenity (romosozumab-aqqg) when the coverage effective date is 90 days or less. Treatment obtained as samples or through a manufacturer’s patient assistance program does not satisfy this current-treatment documentation requirement.

    Clinical Thresholds and Documentation Windows

    Bone mineral density
    Bone mineral density criterionBMD indicating osteoporosis
    T-score thresholdT-score ≤ -2.5
    Applies toPostmenopausal osteoporosis and osteoporosis in biologic males or members assigned male sex at birth
    Very high fracture risk
    Very high fracture risk thresholdT-score less than -3.0
    Other qualifying findingsHistory of fracture within the past 12 months, fractures while on osteoporosis therapy, or multiple fractures
    Additional risk indicators

    Authorization and Documentation Requirements

    Prior Authorization

    Prior Authorization Required

    Prior authorization is required for Evenity (romosozumab-aqqg) under the MassHealth UPPL medical benefit. Submit the required clinical documentation for review before treatment is initiated.

    • Medical benefit prior authorization applies; Evenity may also be available under the pharmacy benefit subject to MassHealth Drug List coverage and criteria.
    • Submit medical-benefit requests to Mass General Brigham Health Plan at 833-895-2611 or fax 888-656-6671.
    Step Therapy

    Required Osteoporosis Therapy History

    Document the member’s required osteoporosis therapy history before requesting Evenity. The applicable pathway requires an inadequate response, adverse reaction, or contraindication involving prior osteoporosis therapies.

    • Postmenopausal or biologic male/male sex assigned at birth: document an inadequate response to an adequate trial of, or an adverse reaction to, one oral bisphosphonate, or a contraindication to all oral bisphosphonates; alternatively, document very high fracture risk.

    About Evenity

    Evenity (romosozumab-aqqg) is a sclerostin inhibitor used to treat osteoporosis in postmenopausal women at high risk for fracture or in patients who have failed or cannot tolerate other available osteoporosis therapy. The policy also recognizes treatment of osteoporosis in biologic males or members assigned male sex at birth as an off-label indication. Coverage requires documented osteoporosis by bone mineral density and specified fracture-risk or prior-treatment criteria.

    Clinical Definitions

    High risk for fracture
    Prior fracture historyHistory of osteoporotic fracture
    Risk-factor basisMultiple risk factors for fracture
    Treatment history basisFailure or intolerance of other available osteoporosis therapy
    Severe osteoporosis
    Recent fragility fractureFragility fracture within the past 12 months
    Fracture during therapyFractures while on osteoporosis therapy
    Very low BMDT-score less than -3.0

    Initial Authorization

    Postmenopausal osteoporosis — Initial therapy criteria

    Initial authorization for postmenopausal osteoporosis requires all applicable criteria.

    Postmenopausal osteoporosis initial therapy

    • Diagnosis and BMD: Indication for treatment of postmenopausal osteoporosis and BMD indicating osteoporosisT-score ≤ -2.5
    • Initial oral-bisphosphonate or very-high-risk pathway

      • Oral bisphosphonate pathway: Inadequate response to an adequate trial or adverse reaction to one oral bisphosphonateone oral bisphosphonate

    Reauthorization

    Evenity reauthorization

    Reauthorization may only be issued for members who have not completed 12 months of treatment.

    Evenity reauthorization: The member has not completed 12 months of treatment and the total treatment duration will not exceed 12 months12 months

    Required Treatment Sequence

    StepRequirementFailure criteria
    1Before Evenity authorization, meet the applicable sequential osteoporosis-treatment criteria: oral bisphosphonate therapy or contraindication; criteria involving denosumab, ibandronate injection, and zoledronic acid 5 mg; and the teriparatide prerequisite (560 mcg/2.24 mL; Bonsity or Forteo).Inadequate response to an adequate trial, adverse reaction, or contraindication, as applicable, for the specified therapies.

    Maximum Treatment Duration

    Quantity limits
    DrugEvenity (romosozumab-aqqg)
    Maximum duration12 months of therapy
    Authorization limitAuthorizations are limited to a maximum of 12 months of therapy
    Policy Summary
    PayerMass General Brigham Health Plan
    PolicyTreatment of Osteoporosis
    Policy CodePolicy N/A
    Change TypeMaterial coverage criteria revision
    Effective DateJan 4, 202748d
    Last ReviewNov 4, 2026
    Next Review DateN/A
    Key ActionSubmit the requested clinical information and supporting medical records for Evenity prior authorization.
    SourceLink
    On This Page
    Coverage CriteriaClinical Thresholds and Documentation WindowsAuthorization and Documentation RequirementsAbout EvenityClinical DefinitionsInitial AuthorizationReauthorizationRequired Treatment SequenceMaximum Treatment Duration
    Contraindication to all oral bisphosphonates
    all oral bisphosphonates
  1. Very high fracture risk: At least one very-high-fracture-risk factorHistory of fracture within the past 12 months; fractures while on osteoporosis therapy; multiple fractures; fractures while on drugs causing skeletal harm such as long-term glucocorticoids; T-score less than -3.0; high risk for falls; history of injurious falls; or very high fracture probability by FRAX or another validated fracture-risk algorithm
  2. Additional therapy or severe osteoporosis pathway

    • Therapy response or contraindication pathway: Inadequate response to an adequate trial or adverse reaction with one, or contraindication to all, of ibandronate injection, denosumab, and zoledronic acid 5 mgibandronate injection; denosumab; zoledronic acid 5 mg
    • Severe osteoporosis: At least one severe-osteoporosis featureHistory of fragility fracture within the past 12 months; fractures while on osteoporosis therapy; T-score less than -3.0; or T-score of -2.5 or below plus a fragility fracture
  3. Teriparatide prerequisite: Inadequate response, adverse reaction, or contraindication to teriparatide 560 mcg/2.24 mL560 mcg/2.24 mL

    Bonsity or Forteo

  4. High risk for falls, history of injurious falls, fractures while on drugs causing skeletal harm, or very high fracture probability by FRAX or another validated fracture-risk algorithm
    Severe osteoporosis
    T-score criterionT-score of -2.5 or below plus a fragility fracture
    Fragility-fracture timingHistory of fragility fracture within the last 12 months
    Additional qualifying findingsFractures while on osteoporosis therapy or a T-score less than -3.0
    New-plan current-therapy documentation
    Lookback periodCoverage effective date ≤ 90 days
    Documentation requiredMedical records documenting that the member is currently receiving the requested drug
    Excluded treatment sourcesTreatment obtained as samples or through a manufacturer's patient assistance program does not satisfy the documentation pathway
  5. For the additional treatment pathway, document an inadequate response, adverse reaction, or contraindication to ibandronate injection, denosumab, and zoledronic acid 5 mg, or document severe osteoporosis as defined by the policy.
  6. Document an inadequate response, adverse reaction, or contraindication to teriparatide 560 mcg/2.24 mL (Bonsity or Forteo).
  7. Documentation Required

    Current Therapy Documentation for New Members

    For members new to the plan, submit medical records showing that the member is currently receiving treatment with the requested drug when the coverage effective date is less than or equal to 90 days.

    • Do not use samples or treatment obtained through a manufacturer’s patient assistance program to establish current therapy.
    Documentation Required

    Clinical Criteria Documentation

    Include records supporting the diagnosis, objective severity, treatment history, and applicable clinical pathway for Evenity. Criteria apply to postmenopausal osteoporosis and, off label, osteoporosis in biologic males/males assigned male at birth.

    • Document osteoporosis by BMD with a T-score of ≤ -2.5.
    • Document one of the following: inadequate response to an adequate trial or adverse reaction to one oral bisphosphonate; contraindication to all oral bisphosphonates; or very high fracture risk.
    • Very high fracture risk may be supported by a fracture within the past 12 months, fractures while on osteoporosis therapy, multiple fractures, fractures while taking drugs causing skeletal harm such as long-term glucocorticoids, T-score < -3.0, high fall risk, injurious falls, or very high FRAX or other validated fracture-algorithm probability.
    • For the additional pathway, document inadequate response, adverse reaction, or contraindication to ibandronate injection, denosumab, and zoledronic acid 5 mg, or severe osteoporosis defined by a fragility fracture within the past 12 months, fractures while on osteoporosis therapy, T-score < -3.0, or T-score ≤ -2.5 plus a fragility fracture.
    • Document inadequate response, adverse reaction, or contraindication to teriparatide 560 mcg/2.24 mL (Bonsity or Forteo).
    Denial Risk

    Failure to Meet Clinical Criteria

    Authorization may be denied when the submitted records do not establish the required osteoporosis diagnosis, objective BMD severity, or applicable prior-treatment pathway.

    • No documented postmenopausal osteoporosis, or no qualifying osteoporosis diagnosis for the biologic male/male sex assigned at birth pathway.
    • BMD does not show osteoporosis (T-score must be ≤ -2.5).
    • Required oral-bisphosphonate trial, adverse reaction, or contraindication is not documented, and no qualifying very-high-fracture-risk exception is established.
    • Required additional therapy history or severe-osteoporosis pathway is not documented, including the required evidence involving ibandronate injection, denosumab, zoledronic acid 5 mg, or teriparatide.
    Denial Risk

    Treatment Duration Exceeds 12 Months

    Reauthorization may be issued only for members who have not completed 12 months of Evenity treatment. The total treatment duration must not exceed 12 months.

    • Authorizations are limited to a maximum of 12 months of therapy.
    • Requests for authorization or reauthorization after completion of 12 months, or that would extend treatment beyond 12 months, may be denied.
    Combined BMD and fracture findingT-score of -2.5 or below plus a fragility fracture
    Oral bisphosphonate contraindication: Contraindication to all oral bisphosphonatesall oral bisphosphonates
  8. Very high fracture risk: At least one very-high-fracture-risk factorHistory of fracture within the past 12 months; fractures while on osteoporosis therapy; multiple fractures; fractures while on drugs causing skeletal harm such as long-term glucocorticoids; T-score less than -3.0; high risk for falls; history of injurious falls; or very high fracture probability by FRAX or another validated fracture-risk algorithm
  9. Additional therapy or severe osteoporosis pathway

    • Therapy response or contraindication pathway: Inadequate response to an adequate trial or adverse reaction with one, or contraindication to all, of denosumab, ibandronate injection, and zoledronic acid 5 mgdenosumab; ibandronate injection; zoledronic acid 5 mg
    • Severe osteoporosis: At least one severe-osteoporosis featureHistory of fragility fracture within the last 12 months; fractures while on osteoporosis therapy; T-score less than -3.0; or T-score of -2.5 or below plus a fragility fracture
  10. Teriparatide prerequisite: Inadequate response, adverse reaction, or contraindication to teriparatide 560 mcg/2.24 mL560 mcg/2.24 mL

    Bonsity or Forteo

  11. Biologic male or male sex assigned at birth — Initial therapy criteria

    Initial authorization for the off-label male indication requires all applicable criteria.

    Biologic male or male sex assigned at birth initial therapy

    • Diagnosis and BMD: Diagnosis of osteoporosis requiring treatment in a biologic male or member assigned male sex at birth and BMD indicating osteoporosisT-score ≤ -2.5
    • Initial oral-bisphosphonate or very-high-risk pathway

      • Oral bisphosphonate pathway: Inadequate response to an adequate trial or adverse reaction to one oral bisphosphonateone oral bisphosphonate
      • Oral bisphosphonate contraindication: Contraindication to all oral bisphosphonatesall oral bisphosphonates
      • Very high fracture risk: At least one very-high-fracture-risk factorHistory of fracture within the past 12 months; fractures while on osteoporosis therapy; multiple fractures; fractures while on drugs causing skeletal harm such as long-term glucocorticoids; T-score less than -3.0; high risk for falls; history of injurious falls; or very high fracture probability by FRAX or another validated fracture-risk algorithm
    • Additional therapy or severe osteoporosis pathway

      • Therapy response or contraindication pathway: Inadequate response to an adequate trial or adverse reaction with one, or contraindication to all, of ibandronate injection, denosumab, and zoledronic acid 5 mgibandronate injection; denosumab; zoledronic acid 5 mg
      • Severe osteoporosis: At least one severe-osteoporosis featureHistory of fragility fracture within the past 12 months; fractures while on osteoporosis therapy; T-score less than -3.0; or T-score of -2.5 or below plus a fragility fracture
    • Teriparatide prerequisite: Inadequate response, adverse reaction, or contraindication to teriparatide 560 mcg/2.24 mL560 mcg/2.24 mL

      Bonsity or Forteo